Before launching a missile, it is necessary to design an efficient safety net for self-protection. In this issue of Cell, Ellermeier et al. (2006) describe the mechanism underlying a biological safety net for the soil bacterium Bacillus subtilis. This bacterium protects itself from a toxic protein it secretes by upregulating an immunity protein, which it does by sequestering a transcriptional repressor at the plasma membrane.
The protein PD-1 (programmed cell death 1) was originally isolated from a thymic T cell line that showed increased expression of this protein following stimuli that promote apoptosis (Ishida et al., 1992) . PD-1 belongs to the CD28 family of immunoreceptors and is expressed by activated T, B, and myeloid cells. Upon interaction with either of two ligands, PD-L1 or PD-L2, PD-1 inhibits antigen stimulation of T and B cells by recruiting the protein tyrosine phosphatase, SHP-2. PD-1 signaling is known to be involved in autoimmunity, allergy, sites of immune privilege, and antitumor immunity (Figure 1 ). In work recently published in Nature, Barber et al. (2005) now show that increased PD-1 expression is a mechanism by which CD8 T cells become functionally impaired during chronic viral infection. This work shows that blocking PD-1 signaling diminishes persistent viral infection in mice and may lead to new treatments for chronic viral infections in humans.
The best evidence that PD-1 suppresses immune activation comes from PD-1-deficient mice, which develop autoimmune diseases (Okazaki et al., 2002) . Single-nucleotide polymorphisms at the PD-1 locus have also been identified in human patients with autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, and type I diabetes (Prokunina and AlarconRiquelme, 2004 ). Both tumors and pathogens take advantage of the inhibitory signal through PD-1 to promote their survival in the host. Indeed, adenovirus can be eliminated more efficiently when PD-1 is absent (Iwai et al., 2003) . However, the precise mechanism by which PD-1 regulates antiviral immunity is not known.
In their recent work, Ahmed and colleagues (Barber et al., 2005) dissect the function of PD-1 in acute and chronic viral infection in mice. They use two different strains of lymphocytic choriomeningitis virus (LCMV): the Armstrong strain that is cleared within a week and the clone 13 strain that establishes a persistent infection. Ahmed and colleagues previously demonstrated that many of the LCMV-specific CD8 T cells are functionally impaired, or exhausted, in the chronic phase of LCMV-clone 13 infection (Zajac et al., 1998) . Although these LCMV-specific CD8 T cells express activation markers such as CD69 and CD44, they lack antiviral effector functions. In the new work, Barber et al. (2005) reveal that PD-1 is highly expressed on the exhausted LCMV-specific CD8 T cells and that blocking the PD-1/PD-L1 interaction during the chronic phase of infection efficiently reanimates exhausted CD8 T cells and promotes In a recent paper in Nature, Barber et al. (2005) show that the immunoreceptor PD-1 is upregulated by "exhausted" T cells during the chronic phase of viral infection in mice. Remarkably, blocking the interaction between PD-1 and its ligand, PD-L1, reactivates these T cells and reduces viral load. Depicted is an antigen-presenting dendritic cell and a CD8 T cell. PD-1 is expressed on activated T, B, and myeloid cells. The PD-ligand 1 (PD-L1) is expressed on T cells, B cells, macrophages, and dendritic cells as well as on nonlymphoid parenchymal cells, whereas PD-L2 is expressed on activated macrophages and dendritic cells. Upon antigen stimulation by cells expressing the major histocompatibility complex (MHC) and a PD-1 ligand, the tyrosine-based switch motif of PD-1 is phosphorylated. This is followed by recruitment of the protein tyrosine phosphatase SHP-2. SHP-2 dephosphorylates downstream effector molecules of the antigen receptor including Syk, ZAP70, and PI3K to inhibit the activation of lymphocytes. PD-1-dependent inhibition is involved in autoimmune diseases (such as systemic lupus erythematosus, type I diabetes mellitus, and rheumatoid arthritis), infection (by both viruses and parasites), allergy (asthma and delayed-type hypersensitivity), immune privilege (feto-maternal tolerance), antitumor immunity (including glioma, leukemia, and cancers of the kidney, esophagus, lung, and ovary), and transplantation immunity (in heart and islet transplants, and in graft-versushost disease).
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clearance of the persisting virus. By contrast, in acute LCMV-Armstrong infection, PD-1 expression is transiently induced and declines quickly to basal levels. The viruses are cleared in a week, and blocking the PD-1/PD-L1 interaction does not affect the number of LCMV-specific CD8 T cells (Barber et al., 2005) . Although the absence of helper CD4 T cells further suppresses the activation of CD8 T cells during chronic viral infection (Zajac et al., 1998) , blocking the PD-1/PD-L1 interaction reanimates CD8 T cells even in the absence of CD4 T cells. Therefore, blocking the activity of PD-1 may be a particularly useful treatment for HIVinfected patients who have very low numbers of CD4 T cells.
How does PD-1 signaling induce exhaustion of CD8 T cells? To answer this question, it is essential to know which cells provide the ligand for PD-1. Although high expression of PD-L1 is found on LCMV-infected splenocytes, it is not documented whether PD-L1-positive cells can act as antigen-presenting cells or target cells. Probst et al. (2005) have recently demonstrated that the presentation of peptide epitopes of LCMV by resting dendritic cells induces CD8 T cell tolerance in a PD-1-dependent manner. Because clone 13, but not Armstrong, LCMV infects antigen-presenting dendritic cells (Sevilla et al., 2000) , exhaustion of CD8 T cells is likely to be induced by PD-L1-expressing dendritic cells infected by LCMV-clone 13. Recent work by Kirchberger et al. (2005) demonstrates that human rhinovirus infection specifically induces PD-L1 and sialoadhesin expression on the surface of dendritic cells. These dendritic cells then suppress allogenic T cells into a hypoproliferative state that cannot be reversed by the addition of exogenous interleukin-2 (IL-2). It is possible that different viruses induce unique sets of costimulatory ligands that determine the fate of antiviral immunity. Viruses that specifically induce expression of PD-L1 and PD-L2 in antigen-presenting cells may downregulate the host immune system and persist longer, whereas those that induce positive costimulatory ligands in antigen-presenting cells may elicit effective antiviral immunity and disappear quickly.
Within one week, PD-L1-deficient mice succumb to LCMV-clone 13 infection and exhibit immunopathologic damage. This is in apparent contradiction to the beneficial effects of blocking the PD-1/PD-L1 interaction during the chronic phase of LCMV-clone 13 infection (Barber et al., 2005) . Although PD-1-deficient mice also develop severe hepatitis at the initial phase of adenovirus infection, they recover quickly and their hepatocytes fully regenerate within 30 days (Iwai et al., 2003) . The reasons why opposite long-term effects are observed in PD-L1-and PD-1-deficient mice are probably due to a difference in the capacity for regeneration of the affected organs and the replication rate of the viruses in the two models.
During infection there may be a limited period of time during which the host immune system can eliminate the virus without damaging host tissue. When the host immune system cannot eliminate viruses within that period of time, PD-1 expression is increased to suppress an excessive immune response that would lead to tissue destruction. The recent report by Chisari and colleagues, indicating that antiviral immunity oscillates in response to hepatitis B virus (HBV) infection, may also support this scenario (Isogawa et al., 2005) . HBV-specific CD8 T cells from an immune donor rapidly migrate into the liver, the site of HBV replication, and secrete interferon-γ (IFNγ), which leads to the suppression of HBV replication within 24 hr. However, following this initial phase, CD8 T cells lose the ability to produce IFNγ and instead begin to produce granzyme B, which leads to the acquisition of cytolytic activity against infected hepatocytes. Because PD-1 expression is observed at the same time as the emergence of granzyme B-positive T cells and persists after the disappearance of viral gene expression at day 7, PD-1 is thought to regulate the oscillatory response of HBV-specific CD8 T cells (Isogawa et al., 2005) . Further analyses may also reveal the involvement of PD-1 in cytokine production, cytolytic activity, and life span of antiviral T cells in acute and chronic viral infections.
To date, many groups have reported that blocking the PD-1/PD-L1 interaction promotes tumor immunity and that patients with tumors expressing PD-L1 and/or PD-L2 have a poorer prognosis. Antitumor T cells may also be exhausted by the expression of PD-1 because, like viral antigens during chronic infections, tumor antigens persist in the host. If this is the case, blocking PD-1 might also reanimate suppressed antitumor T cells leading to the eradication of tumors.
As in tumor immunity and chronic viral infection, autoreactive T cells in autoimmune diseases also persistently encounter their antigens. Although PD-1-deficient mice develop autoimmune disorders, interestingly, different target organs are affected when the PD-1-deficient mice are backcrossed on different mouse strains. Whereas C57BL/6-PD-1-deficient mice develop glomerulonephritis and arthritis, BALB/ c-PD-1-deficient mice develop dilated cardiomyopathy and gastritis (Okazaki et al., 2002) . In NOD mice, a murine model of type I diabetes, blocking the PD-1/PD-L1 interaction in pre-diabetic mice dramatically accelerates the onset and severity of diabetes, similar to that seen in NOD mice lacking PD-1. Although diabetogenic CD8 T cells play a critical role in the induction of insulitis (the inflammation of the insulin-secreting pancreatic islets), they are inactivated in the later phase of diabetes in NOD wild-type mice. Because hyperactivation of CD8 T cells is one characteristic of the NOD mice lacking PD-1, diabetogenic CD8 T cells in NOD wild-type mice may be regulated by a similar mechanism that affects anti-LCMV CD8 T cells during chronic viral infection (Wang et al., 2005) . Although the current observation that anti-LCMV CD8 T cells are suppressed by PD-1 in chronic infection appears similar to the suppression of diabetogenic CD8 T cells by PD-1 in pre-diabetic NOD wildtype mice, there is a critical difference between these two models. Namely, PD-1 expression is rarely detected on CD8 T cells in pre-diabetic NOD wildtype mice, whereas all of the LCMVspecific CD8 T cells during chronic viral infection express PD-1. Thus, it will be important to analyze how the expression of PD-1, PD-L1, and PD-L2 is regulated in both autoimmunity and antiviral immunity for a full understanding of PD-1-dependent immune regulation.
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The report by Ahmed and colleagues opens up new possibilities for the treatment of chronic viral infections. Chronic viral infections are resistant to conventional medications and sometimes lead to tumorigenesis, such as liver cancer due to infections by HBV and hepatitis C virus. The invention of a safe and effective therapy is urgently needed. Interestingly, PD-1 deficiency leads to a relatively mild phenotype when compared to loss of another CD28 family member, CTLA-4, even though engagement of CTLA-4, like PD-1, results in the inhibition of T cell function. Also, the expression of PD-1 is restricted to activated lymphocytes. Thus, blocking PD-1 may have fewer side effects than other potential therapies. The next step may be to demonstrate in human patients that antigenspecific T cells survive during chronic infections, express PD-1, and are reanimated by blocking PD-1 signaling. Such findings could one day lead to the clinical use of PD-1 blockers for the treatment of chronic viral infections.
When hungry, eat your sister... but beware that she does not eat you first! This is the motto of the soil bacterium Bacillus subtilis, according to results from Rich Losick's lab, first reported by González-Pastor et al. (2003) , and now further analyzed by Ellermeier et al. (2006) in this issue of Cell. When B. subtilis is subjected to starvation, two independant gene clusters become transcribed, leading to the synthesis and release in the external medium of two toxic peptides, SkfA and SdpC.
Both factors kill neighboring siblings, thereby releasing nutrients that sustain further growth of the bacteria producing the toxins. However, in order to survive, these bacteria have to protect themselves from the toxic peptides they produce. The SkfA killing factor is pumped out of the bacterial cells by the products of two genes belonging to the skf operon (González-Pastor et al., 2003) . In this issue of Cell, Ellermeier et al. (2006) elucidate the mechanism that provides protection against the SdpC peptide and reveal a remarkable new signal transduction pathway (see Figure 1) .
The core of the new signaling pathway is an operon encoding a soluble DNA binding protein, SdpR, and a transmembrane immunity protein, SdpI. When nutrients are plentiful, the sdpRI operon is not transcribed, due to the presence of the global repressor AbrB, which also represses the operon encoding the SdpC toxin (Fujita et al., 2005 
